ID: ALA4638519

Max Phase: Preclinical

Molecular Formula: C33H24FN5O3

Molecular Weight: 557.59

Molecule Type: Unknown

Representations

Canonical SMILES:  O=C1/C(=C/c2cccnc2)CN(C(=O)c2cc(Cc3n[nH]c(=O)c4ccccc34)ccc2F)C/C1=C\c1cccnc1

Standard InChI:  InChI=1S/C33H24FN5O3/c34-29-10-9-21(16-30-26-7-1-2-8-27(26)32(41)38-37-30)15-28(29)33(42)39-19-24(13-22-5-3-11-35-17-22)31(40)25(20-39)14-23-6-4-12-36-18-23/h1-15,17-18H,16,19-20H2,(H,38,41)/b24-13+,25-14+

Standard InChI Key:  JKSLNSNTHANASW-GUJRAXHGSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Unknown

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 557.59

Molecular Weight (Monoisotopic): 557.1863

AlogP: 4.64

#Rotatable Bonds: 5

Polar Surface Area: 108.91

Molecular Species: NEUTRAL

HBA: 6

HBD: 1

#RO5 Violations: 1

HBA (Lipinski): 8

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 1

CX Acidic pKa: 9.96

CX Basic pKa: 5.12

CX LogP: 3.77

CX LogD: 3.76

Aromatic Rings: 5

Heavy Atoms: 42

QED Weighted: 0.32

Np Likeness Score: -1.11

References

1. Lin S, Zhang L, Zhang X, Yu Z, Huang X, Xu J, Liu Y, Chen L, Wu L..  (2020)  Synthesis of novel dual target inhibitors of PARP and HSP90 and their antitumor activities.,  28  (9): [PMID:32222339] [10.1016/j.bmc.2020.115434]

Source

Source(1):

• Scientific Literature